Navigation Links
Six Presentations on Tocagen's Toca 511 to be Given at the Society of Neuro-Oncology Annual Meeting
Date:11/22/2013

SAN DIEGO, Nov. 22, 2013 /PRNewswire/ -- Tocagen Inc. today announced that six presentations on Toca 511 will be given at the Society of Neuro-Oncology (SNO) Annual Meeting, including interim clinical data from two ongoing Phase I investigational studies, which show that, to date, Toca 511 administration followed by oral courses of Toca FC is safe and well tolerated, and demonstrated antitumor activity in some patients with high grade glioma (HGG). HGG includes glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer. Toca 511 is a retroviral replicating vector that carries a gene for an enzyme that converts orally delivered Toca FC (extended-release 5-FC) into 5-FU, a potent anti-cancer agent.

The data will be presented at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology in San Francisco. Timothy Cloughesy, M.D., director of the Neuro-Oncology Program at the University California, Los Angeles Jonsson Cancer Center and a principal investigator for the Toca 511 resection study, will make an oral presentation titled "Evidence supporting mechanism of action and drug activity in Phase I trial of patients with recurrent high grade glioma administered Toca 511 at the time of surgical resection followed by Toca FC." This presentation will be given on Sunday, Nov. 24, during the Biologic/Immunologic Therapies session from 10:20 a.m. to 12 p.m. PST.

Data from additional studies of Toca 511 will be presented at the conference in the following poster presentations:

  • "A phase I trial of a retroviral replicating vector (Toca 511) in patients with recurrent high grade glioma demonstrates importance of real-time MRI-guided delivery for evaluation of safety and efficacy,"  Friday Nov. 22, 7 to 9 p.m. PST
  • "Intravenous administration of Toca 511 results in uniform distribution of viral spread within the tumor and increased survival in a synergistic, orthotopic mouse glioma model," Saturday Nov. 23, 5 to 7 p.m. PST
  • "Toca 511 gene transfer in combination with temozolomide appears safe and demonstrates synergistic therapeutic efficacy in mouse glioblastoma model," Saturday Nov. 23, 5 to 7 p.m. PST
  • "Prodrug activator gene therapy with a non-lytic retroviral replicating vector (Toca 511) radiosensitizes glioma cells after intracellular generation of 5-fluorouracil," Saturday, Nov. 23, 5 to 7 p.m. PST
  • "Enhancing retroviral replicating vector-mediated prodrug activator gene therapy with engineered mesenchymal stem cells in animal models of glioma," Saturday Nov. 23, 5 to 7 p.m. PST

About Toca 511 & Toca FC

The combination of Toca 511 (vocimagene amiretrorepvec) for injection and Toca FC (flucytosine) extended-release tablets, is being investigated in Phase I studies at leading centers across the US in clinical studies in patients with recurrent high grade glioma, including GBM. Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a prodrug activator gene called cytosine deaminase (CD) selectively to cancer cells. After allowing time for Toca 511 to spread through the tumor, those cancer cells expressing the CD gene can convert the antibiotic drug flucytosine into the anti-cancer drug 5-fluorouracil (5-FU). By producing 5-FU locally, this technology has the potential to produce much higher intratumoral concentrations of 5-FU than can be attained with systemic administration.  In these studies, patients receive a single administration of Toca 511 at the time of surgery (craniotomy or transcranial) followed by repeat cycles of oral Toca FC. To date, a total of 57 patients have received the combination therapy in the two studies.

About Tocagen

Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene therapy products for the treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist. Toca 511 & Toca FC, the company's lead investigational combination product candidate, is being evaluated in two clinical trials in patients with recurrent high grade glioma, including GBM. Tocagen has received grant support from leading brain cancer foundations including, Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation, and Voices Against Brain Cancer (VABC). For more information about Tocagen or Toca 511 please visit www.tocagen.com or www.clinicaltrials.gov.


'/>"/>
SOURCE Tocagen Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics To Webcast Presentations From Companys Investor And Analyst Meeting
2. Star Scientific Files Third-Quarter Financials for 2013; Comments on Companys Corporate Leadership Transition, Roskamp Institute Scientific Presentations at 2013 Annual Society for Neuroscience Convention
3. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
4. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
5. Thoratec Announces Presentations At Investor Conferences For November 2013
6. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
7. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
8. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
9. Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
10. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
11. CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed ... geared towards children of all ages; it is a non-competitive, non-timed event, which is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
Breaking Medicine News(10 mins):